Pregnancy, Sickle Cell Disease and Oxygen Delivery
A source-linked review of what transfusion is intended to correct in pregnancy with Sickle Cell Disease, and why oxygen delivery should be considered together with HbS reduction, maternal-fetal risk and transfusion burden.
Evidence status: External / Pending Review
The study
The TAPS2 feasibility randomised trial examined prophylactic transfusion in pregnant women with Sickle Cell Disease. The study included 35 women: 18 in the intervention group and 17 in the control group. It was designed to test feasibility for a larger trial, not to establish a universal transfusion rule.
No statistically significant difference in maternal or infant outcomes was demonstrated in this small feasibility study. One delayed haemolytic transfusion reaction was reported.
Primary study: Oteng-Ntim et al., TAPS2 feasibility randomised trial, Blood Advances.
What is the transfusion intended to correct?
In this setting, transfusion may serve more than one purpose. It may reduce the proportion of HbS, increase red-cell oxygen-carrying capacity, or prevent a defined maternal or fetal complication. These aims should not be treated as interchangeable.
The central scientific question is therefore not only whether blood is available, but which physiological function needs to be restored and how that function should be measured.
Oxygen delivery and transfusion burden
Pregnancy with Sickle Cell Disease also shows the complexity of repeated donor transfusion. Alloimmunisation, compatibility requirements, donor availability and delayed haemolytic reactions can affect future treatment options.
This does not argue against transfusion when it is clinically indicated. It supports a clearer comparison of approaches that may improve effective oxygen delivery while avoiding some donor-blood-specific constraints.
Relevance to BHOC and Oxygen Therapeutics
This study does not evaluate BHOC, a Biological Hemoglobin Oxygen Carrier, or any other oxygen carrier. It provides clinical context for the broader oxygen-delivery problem: the need to distinguish oxygen-carrying function from HbS reduction and to evaluate both benefit and treatment burden.
Any alternative oxygen-delivery approach would require its own safety, dosing, compatibility and indication-specific clinical evidence.
Source boundary
This page records external research and scientific context. It is not a clinical recommendation and does not establish BHOC efficacy, safety or approval for pregnancy or Sickle Cell Disease.